Lotus Pharmaceuticals, Inc.
LTUS · OTC
6/30/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | -0.04% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | -3,605.97 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | -59.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.54 | 0.77 | 1.54 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 12.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | -49.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |